


# Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia

Verònica Fernàndez,<sup>1</sup> Pedro Jares,<sup>2</sup> Itziar Salaverria,<sup>1</sup> Eva Giné,<sup>3</sup> Sílvia Beà,<sup>1</sup> Marta Aymerich,<sup>1</sup> Dolors Colomer,<sup>1</sup> Neus Villamor,<sup>1</sup> Francesc Bosch,<sup>3</sup> Emili Montserrat,<sup>3</sup> and Elias Campo<sup>1</sup>

<sup>1</sup>Hematopathology Section, Department of Pathology; <sup>2</sup>Genomics Unit; and <sup>3</sup>Department of Hematology, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain

*Haematologica*. 2008 Jan; 93:(1)132-136. DOI: 10.3324/haematol.11694

## Supplementary data



Supplementary Figure 1: qRT-PCR validation of genes ACTL6A, OGG1, PLCB2 and RAPGEF1. 10 patients from the microarray study were used for the validation (CLL2-CLL13) as well as 3 new patients (CLL14-CLL16). White bars correspond to the sample at diagnosis and black bars to the progressed sample. Expression ratios were calculated by the 2<sup>-DDCt</sup> method using b-glucuronidase (GUS) as endogenous control.